Intravascular Oxygenation Catheter
Severe Respiratory Failure (e.g., ARDS)
Pre-clinicalActive
Key Facts
About VQ Biomedical
VQ Biomedical is pioneering a disruptive intravascular oxygenation catheter aimed at treating hospitalized patients with severe respiratory failure, such as ARDS. Its technology seeks to provide a safer, simpler, and less costly alternative to mechanical ventilation and VV-ECMO by performing gas exchange directly within the blood vessels. The company, led by a seasoned team with deep Duke University roots and medical device experience, is in the pre-clinical development stage, backed by venture capital and significant non-dilutive funding from BARDA and DARPA. Recent recognition in the MedTech Innovator 2025 cohort underscores its potential impact in the critical care space.
View full company profile